# BPC-157 FAQ — Frequently Asked Questions > Answers to common questions about BPC-157: mechanism, research doses, half-life, oral vs injection findings, human data, WADA status, and regulatory context. For research purposes only. ## Compound and Mechanism **What is BPC-157 and where does it come from?** BPC-157 is a synthetic 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV and a molecular weight of 1419.5 Da. It was derived from a protein isolated in human gastric juice. It is classified as a pentadecapeptide. Also appears as Stable Gastric Pentadecapeptide BPC 157 and PL 14736 (topical enema formulation studied in IBD trials). --- **How does BPC-157 work at the molecular level?** Four primary signaling nodes: (1) VEGFR2 upregulation — primary driver of endothelial cell proliferation and angiogenesis. (2) Akt-eNOS axis activation — increased nitric oxide production, vasodilation, cell survival. (3) ERK1/2 and FAK-paxillin pathway — fibroblast proliferation and collagen synthesis. (4) NF-kB downregulation — anti-inflammatory, reducing iNOS-derived inflammatory NO while increasing eNOS-derived NO [4][5][11]. These effects are tissue-context-dependent: BPC-157 promotes angiogenesis where healing requires it while opposing pathologic neovascularization elsewhere [11]. --- **What tissues has BPC-157 been studied in beyond the gut?** Musculoskeletal: Achilles tendon detachment and healing [2], tendon fibroblast cultures [3], quadriceps muscle-to-bone reattachment [12], crushed/transected muscle and tendon [1]. Neurological: hippocampal ischemia-reperfusion [5], spinal cord compression [6], dopaminergic system disturbances [7]. Cardiovascular: pulmonary arterial hypertension [8], major vessel occlusion including Budd-Chiari syndrome and portal hypertension [9], lower-extremity ischemia-reperfusion with remote organ protection [14]. ## Dosage and Administration **What are the research doses of BPC-157 used in animal studies?** The most common systemic dose is 10 μg/kg/day intraperitoneal. Many studies include 10 ng/kg and 10 pg/kg arms, all of which are typically active. The dose range spans seven orders of magnitude [2][4][8][12][15]. No lethal dose established in mice at 2 g/kg IV or intragastric [11]. --- **What is the half-life of BPC-157 and how is it metabolized?** Elimination half-life: approximately 15.2 minutes in rats (IV); approximately 5.3 minutes in beagle dogs (IV). Metabolized into constituent amino acids via urine and bile pathways. Linear pharmacokinetics confirmed; no accumulation on repeated dosing [10]. --- **What routes of administration have been studied in animal research?** Nine routes: intraperitoneal, intravenous, intramuscular, oral gavage, ad libitum drinking water, topical cream, local wound application, ophthalmic drops, and intragastric gavage. Intraperitoneal is the most common. Multiple studies compare routes within the same experiment and report consistent activity across routes, including oral [4][8][12][15]. --- **How does BPC-157 compare in activity when given orally versus by injection?** Multiple studies report active effects via oral delivery including comparable outcomes to IP in pulmonary hypertension and quadriceps reattachment models [8][12]. The pharmacokinetic study found very low oral bioavailability in rats [10], creating an apparent paradox. BPC-157's stability in the gastric environment may allow direct local GI tissue effects without significant systemic absorption. For distant tissues, the mechanism underlying oral efficacy is not definitively explained. ## Human Data and Safety **Is there any human clinical data on BPC-157?** Yes, but extremely limited. The 2025 narrative review by McGuire et al. identified three published human studies [13]: (1) Intra-articular knee injection in 14 patients — 87.5% significant pain relief. (2) Intravesical injection for interstitial cystitis in 12 patients — 80–100% symptom resolution. (3) IV safety study in 2 healthy volunteers at up to 20 mg — no adverse events, no clinically meaningful lab changes. Total: 28 participants. No Phase 2 or Phase 3 RCTs completed. --- **What safety signals have been observed?** In rodents: no lethal dose at 2 g/kg IV or intragastric in mice [11]. In three small human pilots: no adverse events in any participant [13]. No published long-term human safety or toxicology studies. The concern about pathologic angiogenesis stimulation in cancer contexts is more nuanced than a simple pro-angiogenic classification — BPC-157 opposes pathologic neovascularization in certain models [11]. Neither rodent nor the limited human data constitute a human safety demonstration. --- **What is the WADA status of BPC-157?** BPC-157 is classified under WADA's S0 Non-Approved Substances category. S0 covers pharmacological substances not approved by any regulatory authority for human therapeutic use. Prohibited both in-competition and out-of-competition for all athletes subject to the World Anti-Doping Code, regardless of route or dose [13]. --- **Is BPC-157 FDA approved?** No. BPC-157 has no FDA approval for any human indication. No active IND application is publicly listed. The related compound PL 14736 (topical enema formulation) was studied in Phase 2 for IBD but did not advance. ## Research Context **What are the proposed mechanisms behind BPC-157's effects on the nervous system?** Two complementary mechanisms in rodent neurological studies: (1) NO system modulation — increased eNOS-derived NO and decreased iNOS-derived inflammatory NO — translating to reduced excitotoxicity and improved vascular protection in ischemic neural tissue [5]. (2) Peripheral NO system modulation achieving central effects through indirect pathways rather than direct BBB penetration [7]. Elevated Egr1 expression (neural plasticity and repair gene) was documented as an upstream event in the neuroprotective cascade [5]. --- **Who has produced most of the BPC-157 research?** The vast majority comes from a single group at the University of Zagreb led by Sikiric and Seiwerth. Limited independent replication is a key barrier to translation [13][16]. He et al. (2022), a Chinese pharmacokinetics group, conducted the principal pharmacokinetic study independently [10]. McGuire et al. (2025), a US musculoskeletal medicine group, conducted the human data narrative review independently [13]. --- **What are the main limitations of the current evidence base?** Four limitations consistently identified: (1) Rodent-dominant evidence base — almost entirely from male Wistar rats. (2) Concentration of research from one group — limited independent replication [13][16]. (3) Extremely limited human data — 28 participants, no completed RCTs. (4) Inconsistent preparation standards — commercial suppliers vary in purity and potency [16]. ## References [1] Brcic L, et al. J Physiol Pharmacol. 2009. PMID: 20388964. [2] Krivic A, et al. J Orthop Res. 2006. DOI: 10.1002/jor.20096. [3] Chang CH, et al. Molecules. 2014. DOI: 10.3390/molecules191119066. [4] Seiwerth S, et al. Front Pharmacol. 2021. DOI: 10.3389/fphar.2021.627533. [5] Vukojevic J, et al. Brain Behav. 2020. DOI: 10.1002/brb3.1726. [6] Perovic D, et al. J Orthop Surg Res. 2019. DOI: 10.1186/s13018-019-1242-6. [7] Vukojevic J, et al. Neural Regen Res. 2022. DOI: 10.4103/1673-5374.320969. [8] Udovicic M, et al. Biomedicines. 2021. DOI: 10.3390/biomedicines9070822. [9] Sikiric P, et al. World J Gastroenterol. 2022. DOI: 10.3748/wjg.v28.i1.23. [10] He L, et al. Front Pharmacol. 2022. DOI: 10.3389/fphar.2022.1026182. [11] Sikiric P, et al. Pharmaceuticals. 2025. DOI: 10.3390/ph18060928. [12] Matek D, et al. Pharmaceutics. 2025. DOI: 10.3390/pharmaceutics17010119. [13] McGuire FP, et al. Curr Rev Musculoskelet Med. 2025. DOI: 10.1007/s12178-025-09990-7. [14] Demirtas H, et al. Medicina. 2025. DOI: 10.3390/medicina61020291. [15] Vukusic D, et al. J Physiol Pharmacol. 2024. DOI: 10.26402/jpp.2024.1.09. [16] Yuan C, et al. Int J Mol Sci. 2026. DOI: 10.3390/ijms27062876. --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.